

Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for July 17, 2015. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and are sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

NNDSS Modernization Initiative Biweekly Update

July 17, 2015

Message Mapping Guide Development Updates

- **Message Mapping Guide (MMG) Status Updates:**
 - **Arboviral and Varicella MMGs** (Requirements Analysis)
 - Arboviral MMG:
 - Requirements analysis is approximately 50% complete.
 - The CDC Surveillance Operations Team (SOT) and Message and Vocabulary (M&V) Team have completed the gap analysis report and are working on the complete list of data elements needed for the guide, which will also include valid values.
 - Varicella MMG:
 - Requirements analysis is approximately 50% complete.
 - The MMG Development Team sent the first draft of the proposed Varicella data element list to the CDC National Center for Immunization and Respiratory Diseases (NCIRD) for review on 7/2/15 and held a follow-up meeting with NCIRD on 7/8/15.
 - **Mumps and Pertussis MMGs** ([Stage 1—Draft Phase](#)):
 - The MMG Development Team sent the test-ready Mumps and Pertussis MMGs, Test Scenarios, and annotated case surveillance worksheets to NCIRD on 7/2/15.
 - Program sign-off is scheduled for 7/17/15.
 - **Congenital Syphilis and STD MMGs** ([Stage II—Pilot Test-ready Draft Phase](#))
 - The MMG Development Team posted pilot test-ready versions of the STD and Congenital Syphilis MMGs and their artifacts to the Draft MMG Web Site.
 - **Generic v2 and Hepatitis MMGs** ([Stage II—Pilot Test-ready Draft Phase](#))
 - The MMG Development Team posted pilot test-ready versions of the Generic v2 and Hepatitis MMGs and their artifacts to the Draft MMG Web Site.
 - No guides are in [Stage III—Final MMG Phase](#) at this time.

Message Validation, Processing, and Provisioning System Updates

- The Message Validation, Processing, and Provisioning System (MVPS) developer delivered the revised message processing functions code for Generic v2, STD, and Hepatitis to CDC on 7/2/15.
 - The installation script for the code had issues and the developer resent it on 7/6/15.

- The MVPS Team is now installing the code and will retest it to confirm resolution of the defects reported to the developer on 6/19/15.
- The MVPS Team received the SQL Server Integration Services (SSIS) package needed to move forward with the cutover from the single-server production environment to the multi-server environment, which occurred on 7/13/15.
 - The MVPS Team will submit a change request (CR) to the CDC Office of the Chief Information Security Officer (OCISO) to update the authority to operate (ATO) to incorporate the MVPS security code and dashboard enhancements—delivered on 7/2/15—as part of the multi-server environment. The typical cycle time for OCISO to approve a CR is 30 days, although the MVPS Team will request an expedited review.
 - The next step after the single-server/multi-server production cutover is for the latest dashboard and message processing code to be moved to the test environment to prepare for user acceptance testing (UAT).
- User acceptance testing of the MVPS Dashboard and message processing functionality by the NMI pilot jurisdictions and CDC programs is planned for the week of 7/27/15.
 - The MVPS Team expects to hold training for the jurisdictions and CDC programs participating in MVPS UAT during the week of 7/27/15. Participants will learn how to use the MVPS Dashboard, what is expected of them during UAT, and how to conduct testing and report findings.
 - On 7/13/15, jurisdiction participants also learned how to work through the CDC Secure Access Management Services (SAMS) authentication system to access the system and enroll other staff from their health department to use MVPS.
- The MVPS Team continues to work on finalizing the data provisioning requirements and data dictionary mapping for Generic v2, Hepatitis, and STD in conjunction with SOT and the M&V Team.
 - The MVPS Team delivered the Generic v2 requirements to the MVPS developer on 6/4/15. The team is now focused on completing the Hepatitis and STD data provisioning requirements in that order.
 - The MVPS Team met with the CDC programs to discuss the Generic v2, Hepatitis, and STD data dictionary and data provisioning design and approach.
 - The team's goal is to submit data provisioning requirements to the MVPS developer before the end of July 2015, with a target of completing Hepatitis requirements on 7/21/15 and STD requirements by 7/30/15. This time frame will allow the MVPS developer to clarify any issues prior to starting their development in August 2015.

Technical Assistance Updates

- **Update on Jurisdiction Implementation:** Note that all pilot jurisdictions are working on both Hepatitis and STD at the same time and are using the test messages and scenarios developed by CDC. Additional test messages may be developed by the jurisdictions.
 - **California:**
 - California continues to work on implementing the messaging plan and has produced a draft data extract.
 - The APHL Technical Assistance (TA) Team is customizing the Rhapsody route for California that will create HL7 messages based on their data extract.
 - **Minnesota:**

- Minnesota has completed the gap analysis and has produced a draft data extract for Hepatitis and STD. The APHL TA Team is reviewing and providing feedback on the data extract. The data extract will be used to customize the Rhapsody route to create HL7 messages.
 - Minnesota has scheduled a Maven upgrade for 7/15/15, but TA work will continue in the test environment.
 - **Oregon**
 - Oregon has created HL7 test messages for Hepatitis and is building the full suite of messages for STD.
 - The APHL TA Team continues to review and provide feedback on test messages as they are created. The APHL TA Team has validated the test messages by using the team's Rhapsody validator.
 - **Michigan:**
 - Michigan has completed the full suite of test messages for Hepatitis and STD and is ready for internal validation.
 - The APHL TA Team has validated the test messages by using the team's Rhapsody validator.
 - **Florida:**
 - Florida has completed the gap analysis for Hepatitis and STD, has created initial HL7 test messages for Hepatitis, and is currently developing STD test messages.
 - The APHL TA Team will review and provide feedback on test messages as they are created.
- CSTE will work with all of the pilot jurisdictions to evaluate the NMI TA efforts.
- Reminder about MMG status:
 - MMGs in Stages I and II are considered draft and may be revised until the time they are finalized.
 - Those jurisdictions selected for pilot testing of the test-ready versions (Stage II) of the MMGs should wait until contacted by the NMI TA Team before using the test-ready MMGs, before implementing surveillance information system changes, and before submitting test messages to CDC.
 - All other jurisdictions should not plan to submit data to CDC or implement MMG-based updates to their surveillance information systems until the final MMGs (Stage III) have been posted.
- For more information about technical assistance:
 - Please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>.
 - For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, APHL, at laura.carlton@aphl.org.
 - For non-pilot jurisdictions: If you have questions or would like to request TA through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email edx@cdc.gov.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.